Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025

Seminal Study Successfully Achieved Primary and Secondary Endpoints, Demonstrating that Hypoimmune (HIP)-Modified Islets are Safe, Evade Detection by the Immune System, Survive, and Function Long-Term and Continue to Produce Insulin in the Patient for Over One Year Following Administration Without Immunosuppression

Sana Expects to File Investigational New Drug (IND) Application and Initiate Phase 1/2 Trial as Early as This Year for SC451, a HIP-Modified, Stem Cell-Derived Therapy Designed as a One-Time Treatment for Patients with Type 1 Diabetes, with a Goal of Long-Term Normal Blood Glucose Without the Need for Insulin Therapy or Immunosuppression